CYT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 kov. 2024 @ 22:00):

Stats
Šios dienos apimtis	1.01M
Vidutinė apimtis	167 616
Rinkos kapitalizacija	108.71M
EPS	$0 ( 2024-03-28 )
Last Dividend	$0.130 ( 2015-11-06 )
Next Dividend	$0 ( N/A )
P/E	-3.25
ATR14	$0.0570 (1.89%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Leonard Braden Michael	Buy	170 589	Common Stock, par value $0.001 per share
2024-03-18	Leonard Braden Michael	Buy	113 777	Common Stock, par value $0.001 per share
2024-03-15	Leonard Braden Michael	Buy	0	Common Stock, par value $0.001 per share
2024-03-15	Leonard Braden Michael	Sell	0	Common Stock, par value $0.001 per share
2024-03-04	Gaiero David G	Buy	2 373	Common Stock

INSIDER POWER
11.44
Last 95 transactions
Buy: 1 923 587 \| Sell: 1 715 632

Tūris Koreliacija

Ilgas: -0.03 (neutral)

Trumpas: 0.00 (neutral)

Signal:(42.394) Neutral

Cyteir Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
EBACU	0.891
TCMD	0.875
ECHO	0.873
TZPSU	0.872
WULF	0.871
TZPS	0.869
JNCE	0.869
MBTCU	0.868
RBNC	0.866
NLTX	0.865

10 Labiausiai neigiamai susiję koreliacijos
VIASP	-0.896
STBA	-0.894
CMBM	-0.893
FBNC	-0.893
MMAC	-0.893
TRST	-0.892
LSAQ	-0.891
CVCY	-0.891
OPI	-0.891
VGFC	-0.891

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Cyteir Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

-0.32
( neutral )

-0.66
( moderate negative )

0.00
( neutral )

-0.45
( neutral )

0.14
( neutral )

Cyteir Therapeutics, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$-1.38M (0.00 %)
EPS:	$-1.250

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.38M (0.00 %)
EPS:	$-1.250

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.201

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.070

Financial Reports:

No articles found.

Cyteir Therapeutics, Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Cyteir Therapeutics, Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.0100	2009-08-06
Last Dividend	$0.130	2015-11-06
Next Dividend	$0	N/A
Payout Date	2015-11-25
Next Payout Date	N/A
# dividends	26	--
Total Paid Out	$2.66	--
Avg. Dividend % Per Year	0.00%	--
Score	1.76	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-20)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

1.76

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.236	1.200	-7.86	-9.43	[0 - 0.3]
returnOnEquityTTM	-0.231	1.500	-3.68	-5.52	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	21.89	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	21.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	21.65	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.000122	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	39.40	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.716	2.00	-0.239	-0.477	[0 - 30]
freeCashFlowPerShareTTM	-0.724	2.00	-0.362	-0.724	[0 - 20]
debtEquityRatioTTM	0.000128	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1 611.81	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.08

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.52	1.000	-0.457	0	[1 - 100]
returnOnEquityTTM	-0.231	2.50	-2.37	-5.52	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.724	2.00	-0.241	-0.724	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.716	2.00	-0.239	-0.477	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-0.983

Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.